IBC Life Sciences announces the 19th Annual International Antibody Engineering Conference will return to San Diego, California on December 7-11, 2008. This meeting serves as the annual forum of the antibody and protein engineering communities, providing insights to drive the future of antibody engineering and the development of immunotherapeutics.
This year’s Keynote speakers have been leading pioneers in this field since its beginning, having contributed many of the advancements that engendered the current revolution in recombinant antibodies and their successful clinical application, making antibody therapy a major new area of modern medicine. Dr. Michael L. Neuberger, Ph.D., from the MRC Laboratory of Molecular Biology, will discuss the evolving technologies of antibody engineering, and Professor Sherie Morrison, Ph.D., from UCLA, will discuss the versatility of antibodies for multiple applications.
In addition, an international speaker faculty will discuss their latest, far-reaching investigations on microarrays and nanotechnology for antibody discovery and analysis; the theory, practice and use of libraries based on restricted amino acid sets; non-antibody scaffolds; intrabodies; novel antibody targets and applications; target selection in relation to efficacy; and a revisiting of the mechanism of antibody action.
The meeting expects more than 700 attendees and is co-located with IBC’s 6th Annual International Antibody Therapeutics Conference being held on December 9-11, 2008.
The Scientific Sponsor of the meeting is The Antibody Society, which is dedicated to furthering the interests of antibody engineering, therapeutic development and the safe and thorough testing of future therapeutic agents.
Complete details on this meeting can be found at http://www.ibclifesciences.com/antibodyeng, and to receive a press pass or arrange an interview with a speaker, email Dawn O’Connor at [email protected].
About IBC Life Sciences
IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com.
Contact: Dawn O'Connor IBC Life Sciences 508 - 614 - 1679 Email Contact
SOURCE: IBC Life Sciences
Comments